CClinicalTrials.gg
CompletedNCT01871519EVOLVEUpdated Mar 29, 2017Results posted

Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs

An interventional study of Balloon kyphoplasty in Compression Fracture of Vertebral Body, Osteoporosis and Cancer, sponsored by Medtronic Spinal and Biologics. Completed at 25 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Medtronic Spinal and Biologics · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
354
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

The study objective is to collect and report 12-month outcomes pertaining to activities of daily living, quality of life, and safety parameters in a Medicare population to be treated with balloon kyphoplasty in the treatment of painful, acute, vertebral body compression fractures (VCFs) associated with either osteoporosis or cancer. The primary objective is to show statistically significant improvement from baseline in the four co-primary endpoints (SF-36v2, PCS, EQ-5D, NRS back pain and ODI) at 3-months; study success will be declared if the primary objective is met. New radiographic fractures, non-surgical management received, VCF-related healthcare resource utilization, and vertebral body height restoration data will also be collected.

02

Conditions studied

  • Compression Fracture of Vertebral Body
  • Osteoporosis
  • Cancer

Keywords

  • vertebral body compression fracture
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Identified as an appropriate candidate for BKP and should have made the choice to have the procedure.
  2. Must be Medicare Eligible (At least 65 years of age or otherwise eligible).
  3. Must have one to three target VCFs, located between T5 and L5, which are due to underlying primary or secondary osteoporosis or cancer.
  4. Cancer patients should not have had a change in chemotherapy regimen within the last month, nor should they have a planned change within the next month from time of enrollment, with the exception of changes in dose.
  5. All VCFs to be treated must have clinical pain symptoms (pain on palpation/percussion over the fractured vertebral body) that correlate with radiographic findings as follows:

    1. Height change: An acute (≤ four month) change in VB height or morphology from a previous x-ray, CT or MRI, with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of one or more grades by the Genant criteria20, OR
    2. Positive MRI or bone scan: VB shows hyperintense signal on STIR sequence MRI, or target VB is positive on radionuclide bone scan.
  6. All VCFs to be treated must have an estimated fracture age of four months or less.
  7. Treatment of all target VCFs must be technically feasible and clinically appropriate for balloon kyphoplasty.
  8. Pre-treatment back pain by numerical rating scale (NRS) score must be ≥ 7 (0-10 scale) and refractory to non-surgical management.
  9. Pre-treatment Oswestry Disability Index must be ≥30 (0 - 100 scale).
  10. Must have life expectancy of ≥ 12 months.
  11. Must declare availability for all study visits.
  12. Must be able to understand the risks and benefits of participating in the study and be willing to provide written informed consent.
  13. Must have the mental capacity necessary to comply with protocol requirements for the 12- month duration of study.

Exclusion criteria

Exclusion Criteria:

  1. Vertebral body morphology or fracture configuration contraindicative of balloon kyphoplasty.
  2. VCFs due to high-energy trauma.
  3. Asymptomatic VCFs or prophylactic treatment of non-fractured vertebral bodies.
  4. VCFs accompanied at the same site by primary tumors of the bone (e.g., osteosarcoma), solitary plasmacytoma or osteoblastic tumors.
  5. Platelet count of \<20,000/uL as measured at the time of hospital admission for the procedure.
  6. Back pain due to causes other than acute fracture.
  7. VCF with a clinically estimated (based on radiographic evidence as well as patient history) age of fracture > four months.
  8. VCF accompanied by objective evidence of secondary radiculopathy or neurologic compromise.
  9. VCFs with the need for spinal surgery beyond balloon kyphoplasty.
  10. Spinal cord compression or canal compromise requiring decompression.
  11. Significant clinical comorbidity that may either contra-indicate surgery or interfere with long-term data collection or follow-up.
  12. Pre-existing conditions contrary to balloon kyphoplasty such as:

    1. Allergy to any components (e.g., bone cement, contrast medium) of the balloon kyphoplasty device/procedure.
    2. Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection.
    3. Irreversible coagulopathy or bleeding disorder.
  13. Contraindications to both MRI and radionuclide bone scan.
  14. Concurrent participation in another clinical study.
  15. Pregnant or intending to become pregnant during the course of the study.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
354 participants (actual)

Study arms

  • Other
    Balloon Kyphoplasty

    This group of patients will be treated with balloon kyphoplasty in the treatment of painful, acute VCFs associated with either osteoporosis or cancer.

    Device: Balloon kyphoplasty

Interventions

  • DeviceBalloon kyphoplasty

    The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.

    Also known as: BKP

05

What researchers measure

Primary outcomes

  1. Back Pain Change From Baseline at 3 Months

    Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."

    Time frame: Baseline, 3 months after surgery

  2. Back Function Change From Baseline by Oswestry Disability Index at 3 Months

    ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).

    Time frame: Baseline, 3 months after surgery

  3. SF-36v2 Physical Component Summary Change From Baseline at 3 Months

    Quality of life was assessed by Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) version 2.0. The SF-36 v2 physical component summary (PCS) score is between 0 and 100, with higher scores denoting better quality of life.

    Time frame: Baseline, 3 months after surgery

  4. Change From Baseline in Quality of Life by the EQ-5D Index at 3 Months

    EQ-5D index scores range from 0 to 1.0 on a scale where 0 = death and 1.0 = perfect health.

    Time frame: Baseline, 3 months after surgery

Secondary outcomes

  1. Back Pain

    Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."

    Time frame: Baseline, 7 days, 30 days, 6 months, 9 months, and 12 months

  2. Back Function (ODI)

    ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).

    Time frame: Baseline, 30 days, 6 months, and 12 months

  3. Quality of Life by SF-36v2 PCS

    Quality of life was assessed by Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) version 2.0. The SF-36 v2 physical component summary (PCS) score is between 0 and 100, with higher scores denoting better quality of life.

    Time frame: Baseline, 30 days, 6 months, and 12 months

  4. Quality of Life by EQ-5D Index Score

    Time frame: Baseline, 30 days, 6 months, and 12 months

  5. Percentage of Subjects Having Daily Living Activities Limited Due to Back Pain in the Previous 2 Weeks

    Time frame: Baseline, 30 days, 3 months, 6 months, and 12 months

  6. The Number of Days With Limited Activities and Bed Rest Due to Back Pain in the Previous 2 Weeks;

    Time frame: Baseline, 30 days, 3 months, 6 months, and 12 months

  7. Ambulatory Status

    Time frame: Baseline, 7 days, 30 days, 3 months, 6 months, 9 months, and 12 months

  8. Barthel Index (Only for Subjects With Osteoporosis)

    For subjects with osteoporosis, the Barthel index was used for rating subject activities of daily living on a scale from 0 (maximum disability) to 20 (no disability).

    Time frame: Baseline, 30 days, 3 months 6 months, and 12 months

  9. Karnofsky Performance Scale

    For subjects with cancer, the Karnofsky performance scale was used for rating subject activities of daily living.The Karnofsky performance scale rates a subject on an 11-step scale from 0 (dead) to 100 (normal, no complaints, no evidence of disease), and a score of 70 is a clinically meaningful threshold for self-care.

    Time frame: Baseline, 30 days, 3 months 6 months, and 12 months

  10. Vertebral Body Height Restoration (Absolute Height Restored as Percent, AHRP)

    AHRP (Absolute height restored as percent) was the amount of height restored in the vertebral body expressed as a percent of estimated pre-fracture (EP) height. Measurements were assessed at anterior, medial, and posterior locations on the vertebral body.

    Time frame: Baseline, pre-discharge, 3 months, and 12 months

  11. Vertebral Body Angle

    The vertebral body kyphosis angle (VBA) was defined as the angle formed by lines drawn parallel to the caudal and cranial fractured vertebral body endplates.

    Time frame: Baseline, pre-discharge, 3 months, and 12 months

  12. Local Cobb Angle

    The local Cobb angle (LCA) was defined as the angle formed by lines drawn parallel to the superior endplate of the vertebral body above and the inferior endplate of the vertebral body below.

    Time frame: Baseline, pre-discharge, 3 months, and 12 months

  13. Subsequent Radiographic Fractures

    A subsequent VCF was defined as any fracture at an index or non-index vertebral body occurring after the initial procedure as compared to baseline. The percentage of subjects having one or more subsequent VCFs is presented.

    Time frame: 3 months and 12 months

  14. Neurological Success Rate

    Neurological functions were assessed preoperatively and postoperatively. Each of the individual functions was comprised of a number of elements. Investigators evaluated whether observations in each function category was normal or abnormal, and documentation of abnormal findings were required for each element in that function. Success for each component was defined as maintenance or improvement from preoperative for all elements. Success for overall neurologic status was defined as successful in all components.

    Time frame: Pre-discharge, 30 days, 3 months, 6 months, and 12 months

06

Results

Posted Feb 7, 2017

Participant flow

A total of 354 subjects were enrolled in this study. Among them, 350 subjects had BKP surgery and 4 subjects were not treated with BKP. Two of the non-treated subjects voluntarily withdrew from the study and 2 subjects were lost-to-follow-up before surgery.

Participant flow — Overall Study
MilestoneBalloon Kyphoplasty
Started350
Completed260
Not completed90
Withdrew: Death26
Withdrew: Lost to follow-up15
Withdrew: Withdrawal by subject49

Outcome measures

PrimaryBack Pain Change From Baseline at 3 Months

Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."

Time frame:
Baseline, 3 months after surgery
Reported as:
Mean · units on a scale
Back Pain Change From Baseline at 3 Months
units on a scaleBalloon Kyphoplasty
Back pain at baseline8.7 ± 1.2
Back pain at 3 Months2.7 ± 2.7
Back pain change-6.0 ± 3.0
PrimaryBack Function Change From Baseline by Oswestry Disability Index at 3 Months

ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).

Time frame:
Baseline, 3 months after surgery
Reported as:
Mean · units on a scale
Back Function Change From Baseline by Oswestry Disability Index at 3 Months
units on a scaleBalloon Kyphoplasty
ODI score at baseline63.4 ± 14.9
ODI score at 3 months27.1 ± 18.8
ODI change-35.3 ± 20.5
PrimarySF-36v2 Physical Component Summary Change From Baseline at 3 Months

Quality of life was assessed by Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) version 2.0. The SF-36 v2 physical component summary (PCS) score is between 0 and 100, with higher scores denoting better quality of life.

Time frame:
Baseline, 3 months after surgery
Reported as:
Mean · units on a scale
SF-36v2 Physical Component Summary Change From Baseline at 3 Months
units on a scaleBalloon Kyphoplasty
SF-36 PCS at baseline24.2 ± 7.0
SF-36 PCS at 3 months36.6 ± 11.2
SF-36 PCS change12.4 ± 11.4
PrimaryChange From Baseline in Quality of Life by the EQ-5D Index at 3 Months

EQ-5D index scores range from 0 to 1.0 on a scale where 0 = death and 1.0 = perfect health.

Time frame:
Baseline, 3 months after surgery
Reported as:
Mean · units on a scale
Change From Baseline in Quality of Life by the EQ-5D Index at 3 Months
units on a scaleBalloon Kyphoplasty
EQ-5D index at baseline0.383 ± 0.212
EQ-5D index at 3 months0.746 ± 0.194
EQ-5D index score change0.351 ± 0.267
SecondaryBack Pain

Back pain was measured using NRS. Patients rated their back pain on a scale from 0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be."

Time frame:
Baseline, 7 days, 30 days, 6 months, 9 months, and 12 months
Reported as:
Mean · units on a scale
Back Pain
units on a scaleBalloon Kyphoplasty
Back pain at baseline8.7 ± 1.2
Back pain at 7 days3.4 ± 2.3
Back pain at 30 days3.2 ± 2.7
Back pain at 6 months2.5 ± 2.7
Back pain at 9 months2.3 ± 2.6
Back pain at 12 months2.4 ± 2.8
SecondaryBack Function (ODI)

ODI Questionnaire was used to assess patient back function. The ODI score ranges from 0-100. The best score is 0 (no disability) and worst is 100 (maximum disability).

Time frame:
Baseline, 30 days, 6 months, and 12 months
Reported as:
Mean · units on a scale
Back Function (ODI)
units on a scaleBalloon Kyphoplasty
ODI score at baseline63.4 ± 14.9
ODI score at 30 days32.5 ± 19.5
ODI score at 6 months25.7 ± 19.0
ODI score at 12 months25.8 ± 19.0
SecondaryQuality of Life by SF-36v2 PCS

Quality of life was assessed by Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) version 2.0. The SF-36 v2 physical component summary (PCS) score is between 0 and 100, with higher scores denoting better quality of life.

Time frame:
Baseline, 30 days, 6 months, and 12 months
Reported as:
Mean · units on a scale
Quality of Life by SF-36v2 PCS
units on a scaleBalloon Kyphoplasty
SF-36 PCS at baseline24.2 ± 7.0
SF-36 PCS at 30 days34.9 ± 9.8
SF-36 PCS at 6 months37.6 ± 11.5
SF-36 PCS at 12 months38.2 ± 12.1
SecondaryQuality of Life by EQ-5D Index Score
Time frame:
Baseline, 30 days, 6 months, and 12 months
Reported as:
Mean · units on a scale
Quality of Life by EQ-5D Index Score
units on a scaleBalloon Kyphoplasty
EQ-5D index at baseline0.383 ± 0.212
EQ-5D index at 30 days0.710 ± 0.196
EQ-5D index at 6 months0.756 ± 0.193
EQ-5D index at 12 months0.758 ± 0.193
SecondaryPercentage of Subjects Having Daily Living Activities Limited Due to Back Pain in the Previous 2 Weeks
Time frame:
Baseline, 30 days, 3 months, 6 months, and 12 months
Reported as:
Number · percentage of participants
Percentage of Subjects Having Daily Living Activities Limited Due to Back Pain in the Previous 2 Weeks
percentage of participantsBalloon Kyphoplasty
Baseline96.3
30 days53.3
3 months31.8
6 months31.0
12 months28.9
SecondaryThe Number of Days With Limited Activities and Bed Rest Due to Back Pain in the Previous 2 Weeks;
Time frame:
Baseline, 30 days, 3 months, 6 months, and 12 months
Reported as:
Mean · days
The Number of Days With Limited Activities and Bed Rest Due to Back Pain in the Previous 2 Weeks;
daysBalloon Kyphoplasty
days of limited activities at baseline11.0 ± 4.6
days of bed rest at baseline6.0 ± 5.9
days of limited activities at 30 days4.7 ± 5.7
days of bed rest at 30 days1.5 ± 3.5
days of limited activities at 3 months2.6 ± 4.6
days of bed rest at 3 months0.7 ± 2.3
days of limited activities at 6 months2.6 ± 4.8
days of bed rest at 6 months0.7 ± 2.5
days of limited activities at 12 months2.2 ± 4.5
days of bed rest at 12 months0.7 ± 2.4
SecondaryAmbulatory Status
Time frame:
Baseline, 7 days, 30 days, 3 months, 6 months, 9 months, and 12 months
Reported as:
Number · percentage of participants
Ambulatory Status
percentage of participantsBalloon Kyphoplasty
Able to walk at baseline42.3
Walk with aid at baseline50.3
Unable to walk at baseline7.4
Able to walk at 7 days59.9
Walk with aid at 7 days38.3
Unable to walk at 7 days1.8
Able to walk at 30 days62.5
Walk with aid at 30 days36.2
Unable to walk at 30 days1.3
Able to walk at 3 months64.5
Walk with aid at 3 months34.1
Unable to walk at 3 months1.4
Able to walk at 6 months62.4
Walk with aid at 6 months36.1
Unable to walk at 6 months1.5
Able to walk at 9 months68.7
Walk with aid at 9 months30.9
Unable to walk at 9 months0.4
Able to walk at 12 months63.2
Walk with aid at 12months35.7
Unable to walk at 12 months1.2
SecondaryBarthel Index (Only for Subjects With Osteoporosis)

For subjects with osteoporosis, the Barthel index was used for rating subject activities of daily living on a scale from 0 (maximum disability) to 20 (no disability).

Time frame:
Baseline, 30 days, 3 months 6 months, and 12 months
Reported as:
Mean · units on a scale
Barthel Index (Only for Subjects With Osteoporosis)
units on a scaleBalloon Kyphoplasty
Barthel index score at baseline16.2 ± 4.0
Barthel index score at 30 days18.8 ± 2.1
Barthel index score at 3 months19.1 ± 2.0
Barthel index score at 6 months19.1 ± 1.8
Barthel index score at 12 months19.1 ± 1.8
SecondaryKarnofsky Performance Scale

For subjects with cancer, the Karnofsky performance scale was used for rating subject activities of daily living.The Karnofsky performance scale rates a subject on an 11-step scale from 0 (dead) to 100 (normal, no complaints, no evidence of disease), and a score of 70 is a clinically meaningful threshold for self-care.

Time frame:
Baseline, 30 days, 3 months 6 months, and 12 months
Reported as:
Mean · units on a scale
Karnofsky Performance Scale
units on a scaleBalloon Kyphoplasty
Karnofsky performance scale at baseline75.7 ± 21.5
Karnofsky performance scale at 30 days88.0 ± 11.0
Karnofsky performance scale at 3 months90.0 ± 14.1
Karnofsky performance scale at 6 months85.0 ± 30.0
Karnofsky performance scale at 12 months96.7 ± 5.8
SecondaryVertebral Body Height Restoration (Absolute Height Restored as Percent, AHRP)

AHRP (Absolute height restored as percent) was the amount of height restored in the vertebral body expressed as a percent of estimated pre-fracture (EP) height. Measurements were assessed at anterior, medial, and posterior locations on the vertebral body.

Time frame:
Baseline, pre-discharge, 3 months, and 12 months
Reported as:
Mean · percentage of pre-fracture height
Vertebral Body Height Restoration (Absolute Height Restored as Percent, AHRP)
percentage of pre-fracture heightBalloon Kyphoplasty
Anterior height Loss from EP at baseline-26.438 ± 22.008
Middle height loss from EP at baseline-27.719 ± 20.861
Posterior height loss from EP at baseline-8.228 ± 10.966
Anterior AHRP at pre-discharge3.897 ± 9.822
Middle AHRP at pre-discharge4.205 ± 9.783
Posterior AHRP at pre-discharge1.280 ± 7.280
Anterior AHRP at 3 months1.511 ± 10.426
Middle AHRP at 3 months2.223 ± 10.076
Posterior AHRP at 3 months0.101 ± 7.474
Anterior AHRP at 12 months1.308 ± 10.765
Middle AHRP at 12 months1.567 ± 10.453
Posterior AHRP at 12 months-0.028 ± 8.284
SecondaryVertebral Body Angle

The vertebral body kyphosis angle (VBA) was defined as the angle formed by lines drawn parallel to the caudal and cranial fractured vertebral body endplates.

Time frame:
Baseline, pre-discharge, 3 months, and 12 months
Reported as:
Mean · degrees
Vertebral Body Angle
degreesBalloon Kyphoplasty
vertebral body angle at baseline-10.474 ± 8.152
Vertebral body angle at pre-discharge-9.522 ± 6.867
Angle change from baseline at pre-discharge1.117 ± 4.137
Vertebral body angle at 3 months-10.119 ± 6.781
Angle change from baseline at 3 months0.633 ± 4.282
Vertebral body angle at 12 months-9.876 ± 6.714
Angle change from baseline at 12 months0.748 ± 4.315
SecondaryLocal Cobb Angle

The local Cobb angle (LCA) was defined as the angle formed by lines drawn parallel to the superior endplate of the vertebral body above and the inferior endplate of the vertebral body below.

Time frame:
Baseline, pre-discharge, 3 months, and 12 months
Reported as:
Mean · degrees
Local Cobb Angle
degreesBalloon Kyphoplasty
Local Cobb angle at baseline-12.919 ± 18.302
Local Cobb angle at pre-discharge-11.190 ± 17.244
Angle change from baseline at pre-discharge2.707 ± 5.102
Local Cobb angle at 3 months-13.439 ± 17.843
Angle change from baseline at 3 months0.253 ± 5.979
Local Cobb angle at 12 months-12.819 ± 18.643
Angle change from baseline at 12 months-0.197 ± 6.106
SecondarySubsequent Radiographic Fractures

A subsequent VCF was defined as any fracture at an index or non-index vertebral body occurring after the initial procedure as compared to baseline. The percentage of subjects having one or more subsequent VCFs is presented.

Time frame:
3 months and 12 months
Reported as:
Number · percentage of participants
Subsequent Radiographic Fractures
percentage of participantsBalloon Kyphoplasty
Subsequent fractures at 3 months36.7
Subsequent fractures at 12 months47.6
SecondaryNeurological Success Rate

Neurological functions were assessed preoperatively and postoperatively. Each of the individual functions was comprised of a number of elements. Investigators evaluated whether observations in each function category was normal or abnormal, and documentation of abnormal findings were required for each element in that function. Success for each component was defined as maintenance or improvement from preoperative for all elements. Success for overall neurologic status was defined as successful in all components.

Time frame:
Pre-discharge, 30 days, 3 months, 6 months, and 12 months
Reported as:
Number · percentage of participants
Neurological Success Rate
percentage of participantsBalloon Kyphoplasty
Neurological success at predischarge79.2
Neurological success at 30 days76.7
Neurological success at 3 months76.4
Neurological success at 6 months74.3
Neurological success at 12 months76.7

Adverse events

Collected over Overall study about 12-month follow up. Non-serious events are listed at a 0.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Balloon Kyphoplasty—79/350 (22.6%)128/350 (36.6%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventBalloon Kyphoplasty
Back painMusculoskeletal and connective tissue disorders17/350
Spinal compression fractureInjury, poisoning and procedural complications11/350
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders5/350
Respiratory failureRespiratory, thoracic and mediastinal disorders4/350
PneumoniaInfections and infestations3/350
FallInjury, poisoning and procedural complications3/350
Cardiac arrestCardiac disorders2/350
CholelithiasisHepatobiliary disorders2/350
Hip fractureInjury, poisoning and procedural complications2/350
Lumbar vertebral fractureInjury, poisoning and procedural complications2/350
Most frequent other events
Showing 10 of 111
Most frequent other events
EventBalloon Kyphoplasty
Back painMusculoskeletal and connective tissue disorders27/350
Spinal compression fractureInjury, poisoning and procedural complications18/350
ArthritisMusculoskeletal and connective tissue disorders11/350
KyphosisMusculoskeletal and connective tissue disorders10/350
FallInjury, poisoning and procedural complications9/350
ArthralgiaMusculoskeletal and connective tissue disorders8/350
SacroiliitisMusculoskeletal and connective tissue disorders6/350
Rib fractureInjury, poisoning and procedural complications4/350
Thoracic vertebral fractureInjury, poisoning and procedural complications4/350
BursitisMusculoskeletal and connective tissue disorders4/350

Baseline characteristics

Age, Continuous
Age, Continuous(years)Balloon Kyphoplasty
Mean78.9 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Balloon Kyphoplasty
Female272
Male78
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Balloon Kyphoplasty
Hispanic or Latino6
Not Hispanic or Latino344
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Balloon Kyphoplasty
American Indian or Alaska Native1
Asian12
Black or African American4
Native Hawaiian or other pacific islander0
White330
Other3
Height
Height(inches)Balloon Kyphoplasty
Mean64.3 ± 3.9
Weight
Weight(lbs)Balloon Kyphoplasty
Mean153.9 ± 36.9
BMI
BMI(kg/m^2)Balloon Kyphoplasty
Mean26.1 ± 5.5
Estimated pre-fracture vertebral body height
Estimated pre-fracture vertebral body height(mm)Balloon Kyphoplasty
Anterior24.940 ± 4.811
Middle24.207 ± 4.264
Posterior26.502 ± 4.397
07

Study locations

25 sites
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • University of Alabama at Birmingham, Division of Neurological Surgery
    Birmingham, Alabama 35294, United States
  • Washington Radiologist Medical Group
    Fremont, California 94538, United States
  • Sutter Health Sacramento Sierra Region
    Sacramento, California 95816, United States
  • Alta Orthopaedic Medical Group
    Santa Barbara, California 93101, United States
  • Torrance Memorial Medical Center
    Torrance, California 90505, United States
  • Radiology Imaging Specialist of Lakeland
    Lakeland, Florida 33805, United States
  • The Back Center
    Melbourne, Florida 32901, United States
  • Physicians & Surgeons of Pocatello
    Blackfoot, Idaho 83221, United States
  • St. Luke's Health System
    Boise, Idaho 83712, United States
  • Central Illinois Neuroscience Foundation
    Bloomington, Illinois 61701, United States
  • Adventist Health Partners
    Hinsdale, Illinois 60521, United States
  • Presence Saint Joseph Medical Center
    Joliet, Illinois 60435, United States
  • Illinois Bone & Joint
    Morton Grove, Illinois 60053, United States
  • Indiana Spine Group
    Carmel, Indiana 46032, United States
  • Advanced Diagnostic Imaging, PC
    Saginaw, Michigan 48603, United States
  • Beaumont Health System
    Troy, Michigan 48085, United States
  • Premier Radiology
    Tupelo, Mississippi 38802, United States
  • Sierra Regional Spine Institute
    Reno, Nevada 89509, United States
  • Consulting Orthopaedic Associates, Inc
    Sylvania, Ohio 43560, United States
  • Clinical Investigations, LLC
    Edmond, Oklahoma 73013, United States
  • James R. Webb, P.C.
    Tulsa, Oklahoma 74133, United States
  • NeuroSpine Institute, LLC
    Eugene, Oregon 97401, United States
  • Scoliosis & Spine Surgery Clinic of Memphis, PLLC
    Memphis, Tennessee 38119, United States
  • The West Clinic
    Memphis, Tennessee 38120, United States
08

References and documents

Publications

  • Beall DP, Chambers MR, Thomas S, Amburgy J, Webb JR Jr, Goodman BS, Datta DK, Easton RW, Linville D 2nd, Talati S, Tillman JB. Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures: The EVOLVE Trial. Neurosurgery. 2019 Jan 1;84(1):169-178. doi: 10.1093/neuros/nyy017. PubMed 29547939 ↗
09

Registry details

Key details

Study ID
NCT01871519
Lead sponsor
Medtronic Spinal and Biologics
Responsible party
Sponsor
First posted
Jun 6, 2013
Start date
May 2013
Primary completion
Dec 2015
Completion
May 2016
Results posted
Feb 7, 2017
Last update
Mar 29, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion